Your Article Summary
See Latest ArticlesBiochemotherapy in the treatment of metastatic melanoma in selected patients
Clinical and Translational Oncology, 06/30/09
Astorga BG et al. - Treatment with BCT shows an increase in RR, some achieving durable CR; nevertheless it cannot be considered a standard treatment and should be employed only in selected patients.
Related Articles
Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy
The Oncologist, 10/30/09
Relevance Score: 70%
Loss of SNF5 expression correlates with poor patient survival in melanoma
Clinical Cancer Research, 10/12/09
Relevance Score: 70%
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09
Relevance Score: 69%
Dormancy of metastatic melanoma
Pigment Cell & Melanoma Research, 11/11/09
Relevance Score: 68%
Metastatic cutaneous malignant melanoma: Spectrum of imaging findings and the role of multimodality imaging
Journal of Medical Imaging and Radiation Oncology (JMIRO), 10/05/09
Relevance Score: 68%
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling
Oncogene, 12/04/09
Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application
Journal of the European Academy of Dermatology and Venereology, 12/02/09
Self-reported screening for skin cancer in Austria
European Journal of Dermatology, 12/02/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09